IRVING, Texas, Aug. 20, 2008 (GLOBE NEWSWIRE) (PRIME NEWSWIRE) -- DelSite Inc., (OTCBB:DSII) today announced DelSite Biotechnologies, Inc., its wholly-owned subsidiary, filed an Investigational New Drug (IND) application with the FDA for its lead product candidate GelVac(tm) nasal powder H5N1 influenza vaccine.
